• Users Online: 632
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 43  |  Issue : 4  |  Page : 178-183

Serum and synovial matrix metalloproteinase-3 as markers of disease activity in early rheumatoid arthritis


1 Lecturer of Rheumatology and Rehabilitation & Physical Medicine, Faculty of Medicine, Benha University, Benha, Egypt
2 Professor of Rheumatology and Rehabilitation & Physical Medicine, Faculty of Medicine, Benha University, Benha, Egypt
3 Lecturer of Chemical & Clinical Pathology, Faculty of Medicine, Banha University, Benha, Egypt
4 President at Banha Teaching Hosptial, Rheumatology and Rehabilitation & Physical Medicine Department, Benha, Egypt

Correspondence Address:
Rasha M Fawzy
Lecturer of Rheumatology and Rehabilitation & physical Medicine, Faculty of Medicine Benha University, MD in Rheumatology and Rehabilitation Benha, Kayiobia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-161X.192257

Rights and Permissions

Background Matrix metalloprotein ase-3 (MMP-3) is one of the MMPs produced in rheumatoid arthritis (RA) joints. Aim The aim of this study was to evaluate serum and synovial fluid (SF) MMP-3 as markers of disease activity in early RA. Patients and methods Thirty early RA patients together with age-matched and sex-matched 12 primary knee osteoarthritis patients and 12 apparently healthy individuals as control groups were enrolled in this study. MMP-3 was measured in serum and SF samples using enzyme-linked immunosorbent assay. Assessment of disease activity in RA patients was carried out using disease activity score-28 (DAS-28), and radiographs of the hands, wrists, and forefeet were obtained and evaluated according to Larsen score. Results As regards mean serum levels of MMP-3, there was a statistically significant elevation in RA patients compared with the control groups (P<0.001). Moreover, the mean SF levels of MMP-3 in RA patients were statistically significantly higher than that in osteoarthritis patients (P<0.001). In RA patients, there was a statistically significant difference (P<0.001) between mean serum and SF levels, being higher in the SF. There was a statistically significant positive correlation (P<0.05) between serum MMP-3 with disease duration, DAS-28, and Larsen score. As regards mean SF MMP-3 levels, there was a high statistically significant positive correlation (P<0.001) with DAS-28 and a statistically significant positive correlation (P<0.05) with Larsen score. Conclusion Elevated serum and synovial MMP-3 levels reflect disease activity in RA patients; thus, it could be used as a useful marker for disease activity. The cross-sectional design of our study did not allow us to produce conclusions with respect to disease course and prognosis. Thus, we recommend further studies on large numbers of patients and serial measurements of MMP-3 to determine the rate of disease progression.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed961    
    Printed10    
    Emailed0    
    PDF Downloaded128    
    Comments [Add]    

Recommend this journal